NasdaqGM:TRVIPharmaceuticals
Trevi Therapeutics (TRVI) Is Up 11.6% After Haduvio Shows Statistically Significant Cough Reduction - What's Changed
Trevi Therapeutics recently announced that its senior management took part in several March 2026 healthcare conferences to present data on Haduvio, an oral nalbuphine ER therapy in development for chronic cough associated with idiopathic pulmonary fibrosis and refractory chronic cough.
The company highlighted that Haduvio is the first investigational therapy reported to deliver a statistically significant reduction in cough frequency across both of these hard‑to‑treat patient groups, in an...